China’s drug regulator has approved MPox’s vaccine for clinical trials

China’s drug regulator has approved the MPox vaccine for clinical trials. This vaccine, developed by China’s local pharmaceutical firm Sinopharm, has been approved for clinical trials by the top drug regulator. This will be the country’s first experimental dose to fight this deadly disease.

The domestically developed Ampox vaccine, manufactured by the Shanghai Institute of Biological Products and developed by Sinopharm, is expected to play an important role in preventing and controlling the infection, the company said in a statement issued on Monday afternoon.

At the same time, no vaccine has been approved for ampox in China yet. Apart from this, at the global level, some vaccines have been approved in the United States, Canada, European Union, Japan and Russia. In China, any vaccine candidate usually has to go through three phases of clinical trials before getting approval in the market.

This process can take years or even decades. However, China’s top drug regulator, the National Medical Products Administration, has launched several accelerated or streamlined channels to facilitate applications for new drugs and vaccines or those in urgent need, according to a report in the government-run China Daily.

The first case was found in 2022

Let us tell you that the first imported case in China was reported in September 2022 and the domestic case was registered in June last year. According to the China Daily report, by the end of July, 2,567 confirmed cases had been reported in the country.